Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

(2020) Abdo A. Elfiky   LIFE SCIENCES

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019

(2020) Yan-Ming Zeng et al.   CHINESE MEDICAL JOURNAL

Immunology of COVID-19: current state of the science

(2020) Nicolas Vabret et al.   IMMUNITY

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

(2020) Christian A. Devaux et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

(2020) Zhen Zhu et al.   JOURNAL OF INFECTION

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

(2020) Jianjun Gao et al.   BioScience Trends

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

(2020) Wei Tang et al.   BMJ-British Medical Journal

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

(2020) Mayla Gabriela Silva Borba et al.   JAMA Network Open

A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy

(2019) Valentina Pistolesi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial

(2018) Titus H Divala et al.   LANCET INFECTIOUS DISEASES

Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients

(2018) Vesa Cheng et al.   Expert Opinion on Drug Metabolism & Toxicology

Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling

(2017) Sam Salman et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine

(2017) Mohamed A. Ghazi Suliman et al.   JOURNAL OF CRITICAL CARE

Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups

(2017) V. A. Bulgakova et al.   TERAPEVTICHESKII ARKHIV

The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies

(2016) S. Sciascia et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia

(2016) Mohammed Al Ghamdi et al.   BMC INFECTIOUS DISEASES

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

UK malaria treatment guidelines 2016

(2016) David G. Lalloo et al.   JOURNAL OF INFECTION

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

(2016) Travis K. Warren et al.   NATURE

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

(2015) Sarah Shalhoub et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Arbidol as a broad-spectrum antiviral: An update

(2014) Julie Blaising et al.   ANTIVIRAL RESEARCH

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

(2014) Ali S Omrani et al.   LANCET INFECTIOUS DISEASES

Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans

(2013) Pan Deng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine

(2012) M M Nyunt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy

(2012) Kristine B. Patterson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Determinants of drug absorption in different ECMO circuits

(2010) E. D. Wildschut et al.   INTENSIVE CARE MEDICINE

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors

(2008) Veena Nukoolkarn et al.   JOURNAL OF THEORETICAL BIOLOGY